MONTREAL--(BUSINESS WIRE)--Dec. 10, 2003--Gemin X Biotechnologies Inc. announced today that it has appointed Andrew R. Jordan, Executive Vice President and Chief Financial Officer of Guilford Pharmaceuticals Inc. (Baltimore, Maryland) to its Board of Directors.
Mr. Jordan joined Guilford Pharmaceuticals upon its inception in September 1993 and was promoted to Executive Vice President and Chief Financial Officer in March 2003. During his tenure, he has guided Guilford in raising in excess of $400 million through an IPO, secondary offerings, PIPEs and recently a $60 million convertible subordinated note offering. Formerly an audit partner with KPMG in Philadelphia, Pennsylvania, Mr. Jordan was involved in working with numerous technology-based companies and gained significant experience in supporting mergers and acquisitions as well as raising capital. Mr. Jordan holds a B.A. from Rutgers College and an M.B.A. from Rutgers Graduate School of Business.
"Andy's specialized experience in corporate finance in the life science industry makes him a valued addition to our Board," said Dan Giampuzzi, President and Chief Executive Officer of Gemin X. "We expect that Andy will assist both the Board and management team in strengthening the Company's capital structure as well as implementing best practices related to matters of corporate governance as part of our audit committee."
"Gemin X is a highly innovative organization with talented employees and Board members, all of whom are dedicated to building a successful pharmaceutical company. It is exciting to be a part of this dedicated group of professionals working in an area as promising as apoptosis, which has the potential to revolutionize the treatment of certain cancers," said Jordan.
Gemin X Biotechnologies Inc. is a Montreal-based biotechnology company that specializes in the modulation of programmed cell death (apoptosis) to discover and develop novel cancer therapeutics. Gemin X's two lead programs focus on pan-inhibitors of Bcl-2 proteins and small molecules that induce apoptosis in p53-defective cancers. Clinical trials for GX015-070, Gemin X's lead compound, are scheduled to begin in 2004. For additional information, please visit Gemin X at www.geminx.com.
Contact:
Gemin X Biotechnologies Inc. Christian Cortis, Ph.D., Director of Business Development 514-281-8989 ccortis@geminx.com or
Atkins + Associates Trista Morrison, Media Relations, 858-527-3490 tmorrison@irpr.com
Source: Gemin X Biotechnologies
